Trial reportGut2004
Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Trial report in Gut, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00119912 (Norwegian Colorectal Cancer Prevention Trial), which is not on this map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Norwegian Colorectal Cancer Prevention Trial
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.The Cochrane database of systematic reviews · 2022Pooled it
- The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis.BMC gastroenterology · 2022Pooled it
- Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Pooled it
- Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.Journal of gastrointestinal cancer · 2016Pooled it
- Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort.Clinical and experimental immunology · 2019Trial
- Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.World journal of gastroenterology · 2007Trial
- The Activity of Antimicrobial Peptides in Pediatric Celiac Disease.Frontiers in pediatrics · 2022Article
- The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorrectal Cancer Screening Cohort.Frontiers in medicine · 2021Article
- Early detection: the impact of genomics.Virchows Archiv : an international journal of pathology · 2017Review
- Advances in Fecal Tests for Colorectal Cancer Screening.Current treatment options in gastroenterology · 2016Article
- Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities.Gut and liver · 2016Review
- Fecal calprotectin in inflammatory bowel disease.Clinical and experimental gastroenterology · 2016Review
- Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.Canadian journal of gastroenterology & hepatology · 2015Review
- Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome.Advanced biomedical research · 2015Article
- A predictive model combining fecal calgranulin B and fecal occult blood tests can improve the diagnosis of colorectal cancer.PloS one · 2014Article
- Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.World journal of gastroenterology · 2012Article
- Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.Digestive diseases and sciences · 2011Review
- A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.International journal of colorectal disease · 2011Article
- Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.International journal of colorectal disease · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScreening for colorectal cancer (CRC) using guaiac based faecal occult blood tests (FOBT) has an estimated programme sensitivity of >60% but <30% for strictly asymptomatic CRC in a single screening round. In search for improved non-invasive tests for screening, we compared a test for faecal calprotectin (PhiCal) with a human haemoglobin immunochemical FOBT (FlexSure OBT).
methodsIn the Norwegian Colorectal Cancer Prevention (NORCCAP) trial, screenees in one screening arm were offered screening with combined flexible sigmoidoscopy (FS) and FlexSure OBT. They were also requested to bring a fresh frozen sample of stool for the PhiCal test which was performed on samples from screenees with CRC (n = 16), high risk adenoma (n = 195), low risk adenoma (n = 592), and no adenoma (n = 1518) (2321 screenees in total). A positive PhiCal test was defined by a calprotectin level > or =50 microg/g.
resultsThe PhiCal test was positive in 24-27% of screenees whether they had no adenoma, low risk adenoma, or high risk adenoma. Ten (63%) of 16 CRCs gave a positive PhiCal test. The total positivity rate in this population was 25% for the PhiCal test compared with 12% for FlexSure OBT, with a sensitivity for advanced neoplasia of 27% and 35%, respectively. Specificity for "any neoplasia" was 76% for the PhiCal test and 90% for FlexSure OBT.
conclusionsIn colorectal screening, the performance of the PhiCal test on a single spot from one stool sample was poorer than a single screening round with FlexSure OBT and cannot be recommended for population screening purposes. The findings indicate a place for FlexSure OBT in FOBT screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.